{"id":15166,"date":"2023-12-11T23:08:50","date_gmt":"2023-12-11T17:38:50","guid":{"rendered":"https:\/\/farratanews.online\/fda-approves-sickle-cell-disease-treatment-that-uses-remarkable-gene-editing-technology\/"},"modified":"2023-12-11T23:08:50","modified_gmt":"2023-12-11T17:38:50","slug":"fda-approves-sickle-cell-disease-treatment-that-uses-remarkable-gene-editing-technology","status":"publish","type":"post","link":"https:\/\/farratanews.online\/fda-approves-sickle-cell-disease-treatment-that-uses-remarkable-gene-editing-technology\/","title":{"rendered":"FDA approves sickle cell disease treatment that uses \u2018remarkable\u2019 gene-editing technology"},"content":{"rendered":"
[ad_1]\n<\/p>\n
Modern medicine is one step closer to potentially curing sickle cell disease.<\/p>\n
On the heels of the U.K.’s authorizing the world\u2019s first gene-edited treatment for sickle cell disease on Nov. 16, the U.S. Food and Drug Administration (FDA) approved the same treatment on Dec. 8.<\/p>\n
“CASGEVY\u2019s approval by the FDA is momentous,” Reshma Kewalramani, M.D., chief executive officer and president of Vertex Pharmaceuticals in Boston<\/u>, said in a statement provided to Fox News Digital.<\/p>\n
ALZHEIMER\u2019S BLOOD TEST COULD HIT THE MARKET IN EARLY 2024, RESEARCHERS SAY<\/u><\/strong><\/p>\n “It is the first CRISPR-based gene-editing therapy<\/u> to be approved in the U.S.”<\/p>\n “These approvals represent an important medical advance with the use of innovative cell-based gene therapies to target potentially devastating diseases and improve public health,” said Peter Marks, M.D., Ph.D., director of the FDA\u2019s Center for Biologics Evaluation and Research, in the agency’s press release.\u00a0<\/p>\n